43P MDM2 alterations in primary brain tumors: A potential niche for targeted therapy

Autor: Puerto, D.A. Gomez, Mirallas, O., Velilla, G., Cerna, J.G. Yaringaño, Ruiz-Pace, F., Gonzalez, A. Hernandez, Valbuena, D.E. López, Gorria, T., Vaz Salgado, M.A., Vinolas, M. Domenech, Sorolla, M. Aguado, Rodriguez, M. Gonzalez, Castro-Henriques Pinto-Machado, M., Garcia, M. Martinez, Dienstmann, R., Pineda, E., Galceran, J. Carles, Balana, C., Sanchez, J.M. Sepulveda, Villar, M. Vieito

Publikováno v: In ESMO Open October 2023 8(1) Supplement 5

Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

Autor: M. Simonelli, E. Garralda, F. Eskens, M. Gil-Martin, C.-J. Yen, R. Obermannova, Y. Chao, S. Lonardi, B. Melichar, V. Moreno, M.-L. Yu, A. Bongiovanni, E. Calvo, S. Rottey, J.-P. Machiels, A. Gonzalez-Martin, L. Paz-Ares, C.-L. Chang, W. Mason, C.-C. Lin, D.A. Reardon, M. Vieito, A. Santoro, R. Meng, G. Abbadessa, F. Menas, H. Lee, Q. Liu, C. Combeau, N. Ternes, S. Ziti-Ljajic, C. Massard

Publikováno v: ESMO Open, 7(5):100562. BMJ Publishing Group
Scientia
ESMO Open, Vol. 7, no.5, p. 100562 (2022)
Dipòsit Digital de la UB
Universidad de Barcelona
ESMO OPEN

Atezolizumab; Isatuximab; Solid tumors Atezolizumab; Isatuximab; Tumores sólidos Atezolizumab; Isatuximab; Tumors sòlids Background The anti-CD38 antibody isatuximab is approved for the treatment of relapsed/refractory multiple myeloma, but there a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76d03cd18a9c37d9a43d28f2c66b0f99
http://hdl.handle.net/2445/190195

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

51P Toxicity profile in early clinical trials with fibroblast growth factor receptor (FGFR) inhibitors (FGFRi): 10-years experience of a drug development unit

Autor: K.I. Rojas Laimito, M. Vieito Villar, B. Fullana Grimalt, R. Berché, C. Hierro Carbo, O. Saavedra Santa Gadea, I. Braña, G. Alonso Casal, V. Galvao de Aguiar, M.J. Lostes Bardaji, M. Oliveira, H. Verdaguer, R. Morales Barrera, C. Garcia Duran, E. Zamora, J. Carles Galceran, T. Macarulla, J. Tabernero, E. Garralda Cabanas

Publikováno v: ESMO Open. 8:100909

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c55925512b870d817b4bc2e9a611d1e7
https://doi.org/10.1016/j.esmoop.2023.100909

6P Circulating tumor DNA (ctDNA) next generation sequencing (NGS): Molecular prescreening for tailoring treatment in clinical trials

Autor: Irene Brana, Elena Garralda, F.J. Ros Montañá, Enriqueta Felip, F. Salva Ballabrera, I. Baraibar Argota, O. Saavedra Santa Gadea, Susana Aguilar, D.A. Acosta Eyzaguirre, Elena Elez, P. Iranzo Gomez, Helena Verdaguer, Guzman Alonso, E. Garcia Torralba, M. Vieito Villar, Natassia Ann Wornham, A. Callejo Perez, J. Tabernero, I. Faull, T. Macarulla Mercade

Publikováno v: Annals of Oncology. 32:S1346-S1348

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::43f1942ea166828d5c75229c0d740252
https://doi.org/10.1016/j.annonc.2021.08.2002